Checkpoint Kinase 2 Gene Mutation clinical trials at UCSF

1 research study open to eligible people

Checkpoint kinase 2 gene mutations can cause cells to repair DNA incorrectly. UCSF is exploring the use of Olaparib and ASTX727 in clinical trials for patients with these mutations. The trials are designed to evaluate the effectiveness of these drugs in treating certain types of cancer.

Showing trials for

  • Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

    open to eligible people ages 18 years and up

    This is a single center, phase I/Ib clinical trial evaluating the combination of the poly adenosine diphosphate-ribose polymerase (PARP) inhibitor olaparib with the DNA methyltransferase (DNMT) inhibitor ASTX727, which is an oral formulation of decitabine with cedazuridine (a cytidine deaminase inhibitor that allows for oral administration). The study population consists of adults with advanced/metastatic solid tumor malignancies with germline or somatic mutations in the HRR pathway (i.e., BReast CAncer gene 1 (BRCA1), BReast CAncer gene 2(BRCA2), Partner And Localizer of BRCA2 (PALB2), ATM, and/or Checkpoint kinase 2 (CHEK2) mutations).

    San Francisco, California

Our lead scientists for Checkpoint Kinase 2 Gene Mutation research studies include .

Last updated: